M. N. Karpova

M. N. Karpova

Auto-generated profile, based on publicly available information

M. N. Karpova

Research Institute of General Pathology and Pathophysiology

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 January 2015 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
MKM. N. Karpova
M. N. Karpova
KZK. A. Zin’kOvskii
K. A. Zin’kOvskii
LKL. V. Kuznetsova
L. V. Kuznetsova
NKN. V. Klishina
N. V. Klishina

1 January 2004 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
IRI. G. Rebrov
I. G. Rebrov
MKM. N. Karpova
M. N. Karpova
AAA. A. Andreev
A. A. Andreev
OKO. S. Kuzina
O. S. Kuzina
MKM. S. Kalinina
M. S. Kalinina
NBN. P. Belykh
N. P. Belykh

Verified
Journal Article
Open access
PDF file
OPOlga Pershina
Olga Pershina
APAngelina Pakhomova
Angelina Pakhomova
Darius WideraDarius Widera
Darius Widera
NENatalia Ermakova
Natalia Ermakova
AEAnton Alexandrovich Epanchintsev
Anton Alexandrovich Epanchintsev
ESEvgenii Skurikhin
Evgenii Skurikhin
In clinical practice, the metabolic syndrome (MetS) is often associated with chronic obstructive pulmonary disease (COPD). Although gender differences in MetS are well documented, little is known about sex-specific differences in the pathogenesis of COPD, especially when combined with MetS. Consequently, it is not clear whether the same treatment regime has comparable efficacy in men and women diagnosed with MetS and COPD. In the present study, using sodium glutamate, lipopolysaccharide, and cigarette smoke extract, we simulated lipid metabolism disorders, obesity, hyperglycemia, and pulmonary emphysema (comorbidity) in male and female C57BL/6 mice. We assessed the gender-specific impact of lipid metabolism disorders and pulmonary emphysema on angiogenic precursor cells (endothelial progenitor cells (EPC), pericytes, vascular smooth muscle cells, cells of the lumen of the nascent vessel), as well as the biological effects of pegylated glucagon-like peptide 1 (pegGLP-1) in this experimental paradigm. Simulation of MetS/COPD comorbidity caused an accumulation of EPC (CD45−CD31+CD34+), pericytes, and vascular smooth muscle cells in the lungs of female mice. In contrast, the number of cells involved in the angiogenesis decreased in the lungs of male animals. PegGLP-1 had a positive effect on lipids and area under the curve (AUC), obesity, and prevented the development of pulmonary emphysema. The severity of these effects was stronger in males than in females. Furthermore, PegGLP-1 stimulated regeneration of pulmonary endothelium. At the same time, PegGLP-1 administration caused a mobilization of EPC (CD45−CD31+CD34+) into the bloodstream in females and migration of precursors of angiogenesis and vascular smooth muscle cells to the lungs in male animals. Gender differences in stimulatory action of pegGLP-1 on CD31+ endothelial lung cells in vitro were not observed. Based on these findings, we postulated that the cellular mechanism of in vivo regeneration of lung epithelium was at least partly gender-specific. Thus, we concluded that a pegGLP-1-based treatment regime for metabolic disorder and COPD should be further developed primarily for male patients.

23 February 2016 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
MKM. N. Karpova
M. N. Karpova
LKL. V. Kuznetsova
L. V. Kuznetsova
KZK. A. Zin’kOvskii
K. A. Zin’kOvskii
NKN. V. Klishina
N. V. Klishina

Verified
Journal Article
Open access
PDF file
APAngelina Pakhomova
Angelina Pakhomova
VNVladimir Evgenievich Nebolsin
Vladimir Evgenievich Nebolsin
OPOlga Pershina
Olga Pershina
VKVyacheslav Andreevich Krupin
Vyacheslav Andreevich Krupin
LSLubov Alexandrovna Sandrikina
Lubov Alexandrovna Sandrikina
ESEvgenii Skurikhin
Evgenii Skurikhin
In clinical practice, the metabolic syndrome can lead to multiple complications, including diabetes. It remains unclear which component of the metabolic syndrome (obesity, inflammation, hyperglycemia, or insulin resistance) has the strongest inhibitory effect on stem cells involved in beta cell regeneration. This makes it challenging to develop effective treatment options for complications such as diabetes. In our study, experiments were performed on male C57BL/6 mice where metabolic disorders have been introduced experimentally by a combination of streptozotocin-treatment and a high-fat diet. We evaluated the biological effects of Bisamide Derivative of Dicarboxylic Acid (BDDA) and its impact on pancreatic stem cells in vivo. To assess the impact of BDDA, we applied a combination of histological and biochemical methods along with a cytometric analysis of stem cell and progenitor cell markers. We show that in mice with metabolic disorders, BDDA has a positive effect on lipid and glucose metabolism. The pancreatic restoration was associated with a decrease of the inhibitory effects of inflammation and obesity factors on pancreatic stem cells. Our data shows that BDDA increases the number of pancreatic stem cells. Thus, BDDA could be used as a new compound for treating complication of the metabolic syndrome such as diabetes.